Modi Ventures — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
Glyphic Biotechnologies develops ProSE™, a high-throughput de novo protein sequencing technology for analyzing proteomes with single-molecule sensitivity.
BiotechDeep TechBerkeley, US
Joshua Yang(Founder & CEO)Daniel Estandian(Founder)Ed Boyden(Founder)Jimmy Yun(Director)
BoardCraig Asher(Director)
Outpace Bio develops engineered protein technologies and cell therapies to treat solid tumors, focusing on protein design and T cell engineering to improve cancer treatment efficacy and safety.
BiotechDeep TechMedical DevicesSeattle, US
Marc Lajoie(Co-founder & Chief Executive Officer)Scott Boyken(Co-founder & Chief Technology Officer)Stanley Riddell(Co-Founder and Scientific Advisor)Aaron Foster(Executive Officer)Charity Scripture(Executive Officer)Eric Soller(Executive Officer)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.